Existing investor Novartis has committed to a $10m private placement alongside the IPO, in which the fibrosis therapy developer is set to raise up to $96m.

Eli Lilly, EMS, Takeda and ST Pharm are in line for exits after muscle disease therapy developer Avidity filed for a $100m initial public offering.

The oncology diagnostics technology provider has filed to go public in the US, with Legend Holdings and Eli Lilly set to exit through the flotation.

Appliance manufacturer Gree bought $89m of shares in an initial public offering in which the oncology therapy developer floated at the top of its range.

The Xiaomi, Intel and Samsung-backed semiconductor and silicon production services provider is valued at more than $420m and is set to float in Shanghai.

Nanoform has filed for a dual listing in Sweden and Finland, marking the first time that a University of Helsinki spinout is seeking an initial public offering.

The Mandatum Life and Ilmarinen-backed nanoparticle technology developer has priced a $76.7m offering that will take place in Sweden and Finland.

The oncology therapeutics developer, a spinoff from Spirogen, has increased the size of its initial public offering from almost $233m to nearly $268m.

AutoNation-backed online car dealership Vroom has filed to raise up to $100m, five months after a series H round valuing it at $1.5bn.

The AstraZeneca cancer drug spinoff floated above its range in an upsized initial public offering and now has a market cap topping $2bn.